Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Didem Torumkuney und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Unit, GSK, London, UK. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Anti-Bacterial Agents, Haemophilus influenzae, Respiratory Tract Infections. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Objectives
To determine the antibiotic susceptibility of community-acquired respiratory tract infection (CA-RTI) isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2018–21 from two hospitals in Tunisia.
Methods
MICs were determined by CLSI broth microdilution, and susceptibility data were interpreted using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Results
S. pneumoniae (n = 58) and H. influenzae (n = 71) isolates were collected; 22.4% of pneumococci were penicillin-susceptible by CLSI oral/EUCAST low-dose breakpoints, but 89.7% were susceptible by EUCAST high-dose/CLSI intravenous administration breakpoints. Susceptibility to ceftriaxone, levofloxacin and moxifloxacin was ≥91.4% by CLSI or PK/PD breakpoints which reduced to 82.8%–87.9% for amoxicillin, amoxicillin/clavulanic acid and cefotaxime. Tetracyclines, macrolides and trimethoprim/sulfamethoxazole were 41.4%–65.5% susceptible, with cefdinir and second-generation cephalosporins less active (24.1%–51.7% susceptible). EUCAST indicated ≥96.6% susceptibility only to high-dose ceftriaxone, moxifloxacin and high-dose levofloxacin. Most H. influenzae (66.2%) were β-lactamase negative, of which six and two isolates were ampicillin-resistant following EUCAST and CLSI criteria, respectively. Antibiotic susceptibility was ≥91.5% (CLSI) except for ampicillin (60.6%) and trimethoprim/sulfamethoxazole (77.5%). Susceptibility by EUCAST was lower than CLSI for most other antimicrobials, except for high dose amoxicillin/clavulanic acid (93.0% by EUCAST, 97.2% high dose PK/PD). Both CLSI and EUCAST showed 100% susceptibility to ceftriaxone.
Conclusions
Few therapeutic options with ≥90% susceptibility for the treatment of S. pneumoniae from CA-RTIs in Tunisia remain. Although H. influenzae isolates displayed higher susceptibility, only ceftriaxone provides 100% coverage for both species following CLSI and EUCAST guidelines. Continued surveillance is important for guiding empiric therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Research Unit, GSK, London, UK.
- Department of Microbiology, Abderrahmen Mami Pneumology Hospital, Ariana, Tunisia.
- Department of Microbiology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.
- Global Affairs, IHMA Europe Sàrl, Rte. De I'Ile-au-Bois 1A, Monthey 1870, Switzerland.
- Infectious Diseases Research Unit, GSK, Gauteng, South Africa.
- Infectious Diseases Medical & Scientific Affairs, GSK, Mumbai, India.
Förderung
- GSK
Zitieren
APA
Torumkuney, D., Slim, L., Hammami, A., Hawser, S., Manenzhe, R., & Manoharan, A. (2025). Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf286
Vancouver
Torumkuney D, Slim L, Hammami A, Hawser S, Manenzhe R, Manoharan A. Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf286
BibTeX
@article{Torumkuney2025,
author = {Torumkuney, Didem and Slim, Leila and Hammami, Adnene and Hawser, Stephen and Manenzhe, Rendani and Manoharan, Anand},
title = {Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf286}
}
EUVIMED